



SEQUENCE LISTING

<110> ONCOTHERAPY SCIENCE, INC.

JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO

<120> Methods for damaging cells using effector functions of anti-FAM3D antibodies

<130> ONC-A0407-US

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 1322

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (298)..(972)

<223>

<400> 1

tccctcaaagg	aggggcagag	cctgcgcagg	gcaggagcag	ctggcccaact	ggcgccccgc	60
aacactccgt	ctcacccctct	gggcccactg	catctagagg	agggccgtct	gtgaggccac	120
tacccctcca	gcaactggga	ggtgggactg	tcagaagctg	gcccagggtg	gtggtcagct	180
gggtcaggga	cctacggcac	ctgctggacc	acctcgccctt	ctccatcgaa	gcagggaagt	240
gggagcctcg	agccctcggg	tggaagctga	ccccaaagcca	cccttcacct	ggacagg	297

atg	aga	gtg	tca	ggt	gtg	ctt	cgc	ctc	ctg	gcc	ctc	atc	ttt	gcc	ata	345
Met	Arg	Val	Ser	Gly	Val	Leu	Arg	Leu	Leu	Ala	Leu	Ile	Phe	Ala	Ile	
1		5						10					15			

gtc	acg	aca	tgg	atg	ttt	att	cga	agc	tac	atg	agc	ttc	agc	atg	aaa	393
Val	Thr	Thr	Trp	Met	Phe	Ile	Arg	Ser	Tyr	Met	Ser	Phe	Ser	Met	Lys	
						20				25			30			

acc	atc	cgt	ctg	cca	cgc	tgg	ctg	gca	gcc	tgc	ccc	acc	aag	gag	atc	441
Thr	Ile	Arg	Leu	Pro	Arg	Trp	Leu	Ala	Ala	Ser	Pro	Thr	Lys	Glu	Ile	
										35		40		45		

cag gtt aaa aag tac aag tgt ggc ctc atc aag ccc tgc cca gcc aac Gln Val Lys Lys Tyr Lys Cys Gly Leu Ile Lys Pro Cys Pro Ala Asn	489
50 55 60	
 tac ttt gcg ttt aaa atc tgc agt ggg gcc gcc aac gtc gtg ggc cct Tyr Phe Ala Phe Lys Ile Cys Ser Gly Ala Ala Asn Val Val Gly Pro	537
65 70 75 80	
 act atg tgc ttt gaa gac cgc atg atc atg agt cct gtg aaa aac aat Thr Met Cys Phe Glu Asp Arg Met Ile Met Ser Pro Val Lys Asn Asn	585
85 90 95	
 gtg ggc aga ggc cta aac atc gcc ctg gtg aat gga acc acg gga gct Val Gly Arg Gly Leu Asn Ile Ala Leu Val Asn Gly Thr Thr Gly Ala	633
100 105 110	
 gtg ctg gga cag gca ttt gac atg tac tct gga gat gtt atg cac Val Leu Gly Gln Lys Ala Phe Asp Met Tyr Ser Gly Asp Val Met His	681
115 120 125	
 cta gtg aaa ttc ctt aaa gaa att ccg ggg ggt gca ctg gtg ctg gtg Leu Val Lys Phe Leu Lys Glu Ile Pro Gly Gly Ala Leu Val Leu Val	729
130 135 140	
 gcc tcc tac gac gat cca ggg acc aaa atg aac gat gaa agc agg aaa Ala Ser Tyr Asp Asp Pro Gly Thr Lys Met Asn Asp Glu Ser Arg Lys	777
145 150 155 160	
 ctc ttc tct gac ttg ggg agt tcc tac gca aaa caa ctg ggc ttc cgg Leu Phe Ser Asp Leu Gly Ser Ser Tyr Ala Lys Gln Leu Gly Phe Arg	825
165 170 175	
 gac agc tgg gtc ttc ata gga gcc aaa gac ctc agg ggt aaa agc ccc Asp Ser Trp Val Phe Ile Gly Ala Lys Asp Leu Arg Gly Lys Ser Pro	873
180 185 190	
 ttt gag cag ttc tta aag aac agc cca gac aca aac aaa tac gag gga Phe Glu Gln Phe Leu Lys Asn Ser Pro Asp Thr Asn Lys Tyr Glu Gly	921
195 200 205	
 tgg cca gag ctg ctg gag atg gag ggc tgc atg ccc ccg aag cca ttt	969

Trp Pro Glu Leu Leu Glu Met Glu Gly Cys Met Pro Pro Lys Pro Phe
 210 215 220

tag ggtggctgtg gctcttcctc agccaggggc ctgaagaagc tcctgcctga 1022

cttaggagtc agagccccgc aggggctgag gaggaggagc aggggggtgct gcgtggaagg 1082
 tgctgcaggt cttgcacgc tgtgtcgccgc ctccctcct cgaaacaga accctccac 1142
 agcacatcctt acccggaaaga ccagcctcag agggtccttc tggaaccagc tgtctgtgga 1202
 gagaatgggg tgcttcgtc agggactgct gacggctggt cctgaggaag gacaaactgc 1262
 ccagacttga gcccaattaa attttatggg tgctggttt gaatgaaaaaaa aaaaaaaaaaa 1322

<210> 2

<211> 224

<212> PRT

<213> Homo sapiens

<400> 2

Met Arg Val Ser Gly Val Leu Arg Leu Leu Ala Leu Ile Phe Ala Ile
 1 5 10 15

Val Thr Thr Trp Met Phe Ile Arg Ser Tyr Met Ser Phe Ser Met Lys
 20 25 30

Thr Ile Arg Leu Pro Arg Trp Leu Ala Ala Ser Pro Thr Lys Glu Ile
 35 40 45

Gln Val Lys Lys Tyr Lys Cys Gly Leu Ile Lys Pro Cys Pro Ala Asn
 50 55 60

Tyr Phe Ala Phe Lys Ile Cys Ser Gly Ala Ala Asn Val Val Gly Pro
 65 70 75 80

Thr Met Cys Phe Glu Asp Arg Met Ile Met Ser Pro Val Lys Asn Asn
 85 90 95

Val Gly Arg Gly Leu Asn Ile Ala Leu Val Asn Gly Thr Thr Gly Ala
 100 105 110

Val Leu Gly Gln Lys Ala Phe Asp Met Tyr Ser Gly Asp Val Met His
 115 120 125

Leu Val Lys Phe Leu Lys Glu Ile Pro Gly Gly Ala Leu Val Leu Val
130 135 140

Ala Ser Tyr Asp Asp Pro Gly Thr Lys Met Asn Asp Glu Ser Arg Lys
145 150 155 160

Leu Phe Ser Asp Leu Gly Ser Ser Tyr Ala Lys Gln Leu Gly Phe Arg
165 170 175

Asp Ser Trp Val Phe Ile Gly Ala Lys Asp Leu Arg Gly Lys Ser Pro
180 185 190

Phe Glu Gln Phe Leu Lys Asn Ser Pro Asp Thr Asn Lys Tyr Glu Gly
195 200 205

Trp Pro Glu Leu Leu Glu Met Glu Gly Cys Met Pro Pro Lys Pro Phe
210 215 220